- Home
- VNDA vs ESPR Comparison
VNDA vs ESPR Comparison
Compare VNDA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- ESPR
- Stock Information
- Founded
- VNDA 2002
- ESPR 2008
- Country
- VNDA United States
- ESPR United States
- Employees
- VNDA N/A
- ESPR N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- ESPR Health Care
- Exchange
- VNDA Nasdaq
- ESPR Nasdaq
- Market Cap
- VNDA 270.2M
- ESPR 319.2M
- IPO Year
- VNDA 2006
- ESPR 2013
- Fundamental
- Price
- VNDA $5.09
- ESPR $2.33
- Analyst Decision
- VNDA Strong Buy
- ESPR Buy
- Analyst Count
- VNDA 2
- ESPR 4
- Target Price
- VNDA $15.50
- ESPR $8.17
- AVG Volume (30 Days)
- VNDA 775.4K
- ESPR 3.4M
- Earning Date
- VNDA 11-06-2024
- ESPR 11-07-2024
- Dividend Yield
- VNDA N/A
- ESPR N/A
- EPS Growth
- VNDA N/A
- ESPR N/A
- EPS
- VNDA N/A
- ESPR N/A
- Revenue
- VNDA $190,858,000.00
- ESPR $295,451,000.00
- Revenue This Year
- VNDA $6.70
- ESPR $199.60
- Revenue Next Year
- VNDA $51.03
- ESPR $19.36
- P/E Ratio
- VNDA N/A
- ESPR N/A
- Revenue Growth
- VNDA N/A
- ESPR 187.12
- 52 Week Low
- VNDA $3.30
- ESPR $0.87
- 52 Week High
- VNDA $6.75
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- VNDA 59.66
- ESPR 54.58
- Support Level
- VNDA $4.56
- ESPR $2.05
- Resistance Level
- VNDA $4.89
- ESPR $2.25
- Average True Range (ATR)
- VNDA 0.18
- ESPR 0.12
- MACD
- VNDA 0.04
- ESPR -0.00
- Stochastic Oscillator
- VNDA 66.67
- ESPR 61.54
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.